KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Bausch Health Companies (BHC) EBIAT (2016 - 2025)

Bausch Health Companies' EBIAT history spans 17 years, with the latest figure at -$103.0 million for Q4 2025.

  • For Q4 2025, EBIAT fell 210.75% year-over-year to -$103.0 million; the TTM value through Dec 2025 reached $118.0 million, up 253.25%, while the annual FY2025 figure was $120.0 million, 360.87% up from the prior year.
  • EBIAT for Q4 2025 was -$103.0 million at Bausch Health Companies, down from $179.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $412.0 million in Q3 2022 and bottomed at -$610.0 million in Q1 2021.
  • The 5-year median for EBIAT is -$65.0 million (2022), against an average of -$85.0 million.
  • The largest annual shift saw EBIAT tumbled 772.13% in 2022 before it soared 1014.29% in 2025.
  • A 5-year view of EBIAT shows it stood at $61.0 million in 2021, then crashed by 772.13% to -$410.0 million in 2022, then surged by 90.49% to -$39.0 million in 2023, then surged by 338.46% to $93.0 million in 2024, then crashed by 210.75% to -$103.0 million in 2025.
  • Per Business Quant, the three most recent readings for BHC's EBIAT are -$103.0 million (Q4 2025), $179.0 million (Q3 2025), and $128.0 million (Q2 2025).